Tai Y, Lin L, Xing L, Cho S, Yu T, Acharya C, et al. APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia. 2019;33:426-438 pubmed publisher

Lee L, Draper B, Chaplin N, Philip B, Chin M, Galas Filipowicz D, et al. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. Blood. 2018;131:746-758 pubmed publisher

Flint S, Gibson A, Lucas G, Nandigam R, Taylor L, Provan D, et al. A distinct plasmablast and naïve B-cell phenotype in primary immune thrombocytopenia. Haematologica. 2016;101:698-706 pubmed publisher

Salazar Camarena D, Ortiz Lazareno P, Cruz A, Oregon Romero E, Machado Contreras J, Muñoz Valle J, et al. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus. Lupus. 2016;25:582-92 pubmed publisher

Lepse N, Land J, Rutgers A, Kallenberg C, Stegeman C, Abdulahad W, et al. Toll-like receptor 9 activation enhances B cell activating factor and interleukin-21 induced anti-proteinase 3 autoantibody production in vitro. Rheumatology (Oxford). 2016;55:162-72 pubmed publisher

Lougaris V, Gallizzi R, Vitali M, Baronio M, Salpietro A, Bergbreiter A, et al. A novel compound heterozygous TACI mutation in an autosomal recessive common variable immunodeficiency (CVID) family. Hum Immunol. 2012;73:836-9 pubmed publisher